# Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

> **NCT04842617** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 5274 (actual)

## Conditions studied

- Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

## Interventions

- **DRUG:** SHR6390
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04842617
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-30
- **Primary completion:** 2026-10-31
- **Final completion:** 2031-10-31
- **Target enrollment:** 5274 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842617, "Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04842617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*